ATE314354T1 - Radiopharmazeutika für die diagnose von alzheimer - Google Patents

Radiopharmazeutika für die diagnose von alzheimer

Info

Publication number
ATE314354T1
ATE314354T1 AT01982450T AT01982450T ATE314354T1 AT E314354 T1 ATE314354 T1 AT E314354T1 AT 01982450 T AT01982450 T AT 01982450T AT 01982450 T AT01982450 T AT 01982450T AT E314354 T1 ATE314354 T1 AT E314354T1
Authority
AT
Austria
Prior art keywords
radiopharmaceutics
alzheimer
diagnosis
Prior art date
Application number
AT01982450T
Other languages
English (en)
Inventor
Christoph-Stephan Hilger
Bernd Johannsen
Joerg Steinbach
Peter Maeding
Meredith Halks-Miller
Richard Horuk
Harald Dinter
Raju Mohan
Joseph E Hesselgesser
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of ATE314354T1 publication Critical patent/ATE314354T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT01982450T 2000-11-06 2001-11-01 Radiopharmazeutika für die diagnose von alzheimer ATE314354T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24629900P 2000-11-06 2000-11-06
PCT/EP2001/012607 WO2002036581A1 (en) 2000-11-06 2001-11-01 Radiopharmaceuticals for diagnosing alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE314354T1 true ATE314354T1 (de) 2006-01-15

Family

ID=22930075

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01982450T ATE314354T1 (de) 2000-11-06 2001-11-01 Radiopharmazeutika für die diagnose von alzheimer

Country Status (29)

Country Link
US (2) US6676926B2 (de)
EP (1) EP1332138B1 (de)
JP (1) JP4234425B2 (de)
KR (1) KR20030045167A (de)
CN (1) CN1473158A (de)
AR (1) AR035366A1 (de)
AT (1) ATE314354T1 (de)
AU (2) AU2002214034B2 (de)
BG (1) BG107762A (de)
BR (1) BR0115150A (de)
CA (1) CA2424598A1 (de)
DE (1) DE60116365T2 (de)
EA (1) EA006199B1 (de)
EE (1) EE200300216A (de)
HR (1) HRP20030459A2 (de)
HU (1) HUP0301710A3 (de)
IL (1) IL155191A0 (de)
JO (1) JO2207B1 (de)
MX (1) MXPA03003759A (de)
NO (1) NO20032007L (de)
NZ (1) NZ525303A (de)
PE (1) PE20020531A1 (de)
PL (1) PL361631A1 (de)
SK (1) SK287495B6 (de)
TW (1) TWI238820B (de)
UY (1) UY27003A1 (de)
WO (1) WO2002036581A1 (de)
YU (1) YU33203A (de)
ZA (1) ZA200304409B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
EP1438298B1 (de) 2001-10-22 2010-01-27 Pfizer Products Inc. Piperazinderivate mit ccr1-rezeptor-antagonistischer wirkung
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
EP1620373B1 (de) * 2003-05-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft Vorrichtung und verfahren zum nucleophilen fluorieren
EP2610234A1 (de) * 2004-02-24 2013-07-03 The General Hospital Corporation Katalytische Radiofluorierung
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
KR100778888B1 (ko) * 2005-11-29 2007-11-28 재단법인서울대학교산학협력재단 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물
CA2663121C (en) 2006-09-08 2016-01-19 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US9717719B2 (en) 2006-09-08 2017-08-01 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
CN101563305A (zh) * 2006-12-21 2009-10-21 哈默史密斯网上成像有限公司 放射性标记方法
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
US20100312105A1 (en) * 2007-10-31 2010-12-09 Alseres Pharmaceuticals, Inc. Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
EP3231804B1 (de) 2008-03-21 2021-03-03 The General Hospital Corporation Verbindungen und zusammensetzungen für den nachweis und die behandlung von morbus alzheimer und verwandten erkrankungen
EP2161256A1 (de) * 2008-09-08 2010-03-10 Atomic Energy Council - Institute of Nuclear Energy Research Verbindung mit Carboxylat-Ester und bifunktionalen N2S2-Liganden-Gruppen und Herstellungsverfahren davon
EP2163541A1 (de) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazin-Derivate zur Bindung und Abbildung von Amyloidplaques und deren Verwendung
US20110077222A1 (en) * 2009-09-30 2011-03-31 Mallinckrodt Inc. Sustained-Release Opiate and Opiate Derivative Compositions
TW201201846A (en) * 2010-02-08 2012-01-16 Bayer Schering Pharma Ag Iodo precursor for a PET imaging agent of amyloid plaques
WO2011110511A1 (en) * 2010-03-11 2011-09-15 Bayer Pharma Aktiengesellschaft Spect imaging agents of amyloid plaques
US9572787B2 (en) 2011-05-19 2017-02-21 Rhode Island Hospital Inhibition of renal fibrosis
JP6584322B2 (ja) 2013-12-27 2019-10-02 国立大学法人 東京医科歯科大学 アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
HRP20211156T1 (hr) * 2015-08-28 2021-12-24 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654013B2 (en) 1991-03-13 1994-10-20 Regents Of The University Of Minnesota 2-hydroxy-3(4-iodophenyl)-1-(4-phenylpiperidinyl) propane
EP0524146A1 (de) 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituierte Piperazinderivate
GB9413772D0 (en) 1994-07-08 1994-08-24 Wyeth John & Brother Ltd 5-HT1A ligands
WO1997040010A1 (en) * 1996-04-24 1997-10-30 Emory University Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites
EP0920306A2 (de) 1996-07-12 1999-06-09 Leukosite, Inc. Chemokinrezeptor antagoniste und verfahren zu deren herstellung
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
KR20010108394A (ko) 1999-03-26 2001-12-07 다비드 에 질레스 신규 화합물
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer

Also Published As

Publication number Publication date
DE60116365T2 (de) 2006-08-24
HUP0301710A2 (hu) 2003-11-28
NO20032007L (no) 2003-07-02
WO2002036581A1 (en) 2002-05-10
AU2002214034B2 (en) 2006-01-05
EE200300216A (et) 2003-08-15
US6676926B2 (en) 2004-01-13
SK5472003A3 (en) 2003-10-07
US6872381B1 (en) 2005-03-29
HUP0301710A3 (en) 2007-03-28
UY27003A1 (es) 2002-07-31
EA006199B1 (ru) 2005-10-27
PL361631A1 (en) 2004-10-04
YU33203A (sh) 2006-05-25
EP1332138A1 (de) 2003-08-06
EP1332138B1 (de) 2005-12-28
EA200300507A1 (ru) 2003-12-25
TWI238820B (en) 2005-09-01
AR035366A1 (es) 2004-05-12
BG107762A (en) 2004-03-31
NZ525303A (en) 2004-10-29
BR0115150A (pt) 2003-12-30
CA2424598A1 (en) 2002-05-10
MXPA03003759A (es) 2003-07-28
SK287495B6 (sk) 2010-12-07
NO20032007D0 (no) 2003-05-05
AU1403402A (en) 2002-05-15
JO2207B1 (en) 2004-10-07
HRP20030459A2 (en) 2005-04-30
ZA200304409B (en) 2004-09-06
IL155191A0 (en) 2003-11-23
JP4234425B2 (ja) 2009-03-04
JP2004513123A (ja) 2004-04-30
KR20030045167A (ko) 2003-06-09
CN1473158A (zh) 2004-02-04
PE20020531A1 (es) 2002-06-15
DE60116365D1 (de) 2006-02-02
US20020131932A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
DE60116365D1 (de) Radiopharmazeutika für die diagnose von alzheimer
DE60141316D1 (de) Indikator für die plasmasterilisation
DE60022413D1 (de) Operationsvorrichtung für die Kornea
ATE355293T1 (de) Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten
DE60139170D1 (de) Ultraschall Diagnostik-Anordnung
DE60022540T2 (de) Befestigungselement für die haut
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE50206759D1 (de) Imprägnierlösung für kosmetiktücher
ID23358A (id) Gsp berbantuan tanpa kawat dengan menggunakan lokasi rujukan
DE60238145D1 (de) Gesundheitsüberwachungssystem für schwangere Frauen
DE60021328D1 (de) Herstellungsverfahren für die Herstellung von Aluminat-Phosphor
DE60221457D1 (de) System für die Bleiche von verfärbten Zähnen
DE60227987D1 (de) Drainagevorrichtung für den harnleiter
DE60206017D1 (de) Abdeckung für bohrlochfilter
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
DE69931509D1 (de) Zubereitungen für die mundhöhle
DE60015449D1 (de) Phantom für Bildgebungsvorrichtung
DE60217220D1 (de) Strategie für die Reformierung von Diesel
DE60236049D1 (de) Elektroakustische Umwandlung für Fahrzeuge
ATA17512001A (de) Halterung für eine abdeckleiste
DE50205044D1 (de) Überwachungssystem für einen fahrzeuginnenraum
EP1365790A4 (de) Diagnostischer indikator für thymusfunktion
EP1448056A4 (de) Surfactant-protein d für die vorbeugung und diagnose von lungenemphysem
DE50100883D1 (de) Dichtung für ein Endoskop
DE69927016D1 (de) Durchscheinendes reinigungsstück für die körperpflege

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties